- Home
- CRSP vs ESAB Comparison
CRSP vs ESAB Comparison
Compare CRSP & ESAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CRSP | ESAB |
|---|---|---|
| Founded | 2013 | 1904 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Office Equipment/Supplies/Services |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 5.6B |
| IPO Year | 2016 | 2022 |
Fundamental Metrics
Financial Performance| Metric | CRSP | ESAB |
|---|---|---|
| Price | $55.44 | $67.11 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 22 | 11 |
| Target Price | $87.56 | ★ $126.91 |
| AVG Volume (30 Days) | ★ 1.3M | 815.9K |
| Earning Date | 11-09-2026 | 10-28-2026 |
| Dividend Yield | N/A | ★ 0.73% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ 1.27 |
| Revenue | $289,590,000.00 | ★ $2,842,555,000.00 |
| Revenue This Year | $1,063.30 | $7.77 |
| Revenue Next Year | $283.48 | $9.43 |
| P/E Ratio | ★ N/A | $53.15 |
| Revenue Growth | ★ 9169.85 | 3.71 |
| 52 Week Low | $44.12 | $64.86 |
| 52 Week High | $78.48 | $137.42 |
Technical Indicators
Market Signals| Indicator | CRSP | ESAB |
|---|---|---|
| Relative Strength Index (RSI) | 52.39 | 37.09 |
| Support Level | $50.56 | $64.86 |
| Resistance Level | $60.04 | $83.20 |
| Average True Range (ATR) | 2.83 | 2.55 |
| MACD | -0.03 | 0.40 |
| Stochastic Oscillator | 51.06 | 13.91 |
Price Performance
Historical ComparisonAbout CRSP CRISPR Therapeutics AG
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
About ESAB ESAB Corporation
ESAB, spun off from Colfax in 2022, is a leading manufacturer of equipment and consumables used in welding, cutting, and joining applications. Alongside competitors Lincoln Electric and ITW's Miller brand, ESAB is one of the top three players in the welding space. ESAB generated roughly $2.8 billion in revenue in 2025.